Retatrutide

What it is

GLP-1 and GIP are natural gut hormones that influence appetite, digestion speed, and insulin release after eating, and several approved medicines already target one or both of them. Retatrutide adds a third target, the glucagon receptor, which is tied to how the liver processes fat and how much energy the body spends at rest, making it what researchers call a triple agonist.

The compound is a large, 39 amino acid peptide given by injection under the skin. Trials have used a schedule that starts at a low amount and steps it up every few weeks, a design meant to reduce digestive side effects while the body adjusts.

How it is studied

The evidence for retatrutide comes from randomized, placebo-controlled human trials, including a pivotal Phase 3 obesity trial with a registered trial number and a separate Phase 3 trial in early type 2 diabetes, plus substudies looking at conditions such as sleep apnea and knee osteoarthritis. Trial periods ranged from 40 to 80 weeks, with an extension group followed to 104 weeks.

What studies report

• Beyond weight and blood sugar, retatrutide's registered Phase 3 program includes dedicated substudies testing it against obstructive sleep apnea severity and knee osteoarthritis pain, using a shared trial design across people with obesity who also have one of those two conditions; results from these substudies were not yet published in a peer-reviewed paper as of the source reviewed here, only the trial design. [1]
• In the pivotal 80-week obesity trial, the highest amount studied was linked to an average weight loss of about 28 percent, with an extension group followed to 104 weeks reaching about 30 percent, and about 45 percent of participants on that amount lost 30 percent or more of their body weight. [2]
• In a 40-week trial in adults with early type 2 diabetes, retatrutide lowered HbA1c, a blood test reflecting average blood sugar, by 1.7 to 2.0 percentage points more than baseline, alongside weight loss of up to about 17 percent on the highest amount, with digestive side effects as the main safety signal. [3]

What is not known

Because retatrutide has not yet completed the regulatory review process, there is no long-term safety record outside its clinical trials, and its manufacturer's own materials describe an approval decision as still ahead rather than granted. The trials reviewed here compared the compound mainly against placebo, so how its effects compare directly with already-approved single- or dual-hormone medicines in a head-to-head trial is not addressed in the sources reviewed. The substudies testing retatrutide against sleep apnea severity and knee osteoarthritis pain had a published trial design at the time of this review, but their results had not yet appeared in a peer-reviewed paper.

Reported adverse findings

• Trials flagged an increase in heart rate as a common finding requiring monitoring, along with digestive side effects typical of this class of hormone-receptor-targeting compounds, and a caution around personal or family history of a rare thyroid cancer. [3]

Regulatory status

Retatrutide is an investigational compound, meaning it is still being tested and is not approved for sale anywhere. Its maker has stated it expects to submit for FDA approval, with a decision realistically expected roughly a year or more after that submission; until an approval is granted, retatrutide is not an approved medicine in any jurisdiction identified in the sources reviewed.